IJNRD.ORG ISSN : 2456-4184
INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT (IJNRD) | IJNRD.ORG
An International Open Access, Peer-reviewed, Refereed Journal

Title: - A review article on Black fungus

***Thakur gabada, Prof Fareen Shah, Ishan Bothara, Mukul Ingole**

Jagadamba Institute of Pharmacy & Research kalamb Dist (Yavatmal) 445401

➢ Abstract

As a rare "opportunistic" fungal disease, the black fungus infection has severely impacted the post-COVID-19 recoveries and imposed an additional burden on our medical and healthcare management system. After the first phase of COVID-19, the second wave affected a lot of Indians with a mysterious fungal infection known as Mucormycosis. Here, we reviewed clinical pathogenesis, signs, symptoms, and treatment against black fungus. The conclusion revealed that the use of immunosuppressants to combat COVID-19 also increases the risk of getting infected with mucormycosis. Patients with hyperglycemia, ketoacidosis, solid organ or bone marrow transplantation, liver cirrhosis, and neutropenia are more susceptible to being attacked by Mucormycosis molds. Early diagnosis, removal of predisposing factors, timely antifungal therapy with surgical removal of all infected tissues, and adjunctive therapies are four major factors to eradicate Mucormycosis. As a result, millions of lives have already been lost. As a result of the mutation, the virus is constantly changing its traits, including the rate of disease transmission, virulence, pathogenesis, and clinical signs. A recent analysis revealed that some COVID-19 patients were also coinfected with a fungal disease called mucormycosis (black fungus). India has already categorized the COVID-19 patient black fungus outbreak as an epidemic. Only a few reports are observed in other countries. The immune system is weakened by COVID-19 medication, rendering it more prone to illnesses like black fungus (mucormycosis). COVID-19, which is caused by a B.1.617 strain of the SARS-CoV-2 virus, has been circulating in India since April 2021. Mucormycosis is a rare fungal infection induced by exposure to a fungus called mucormycete.

➢ Introduction

Mucormycosis is a fungal infection caused by Mucorales. Among three genera, such as Rhizopus, Rhizomucor, and Mucor, they cause 75% of mucormycosis (Kontoyiannis et al., 2010). The infection occurs in the upper airways in the form of granulomatous invasion and may gradually move forward into sinuses and/or brain tissue.

As a rare "opportunistic" fungal disease, the black fungus infection has severely impacted the post-COVID-19 recoveries and imposed an additional burden on our

medical and healthcare management system. Together with the uncertain treatment modalities at the beginning of the pandemic, the indiscriminate use of a plethora of medications, including steroids and antibiotics, has helped drive the surging cases of black fungus-associated complications. However, the persistent low oxygen level in blood with high iron levels, along with prolonged hospitalization of COVID-19 patients under the aid of mechanical ventilators, are the key contributors to contracting the black fungus infection. A black fungus is a group of molds commonly known as mucormycosis, while the resultant infection is termed mucormycosis. Mucormycosis is reported to be more prevalent among COVID-19 patients with precedent medical conditions like hyperglycemia with prescribed medications, including steroids. Mucormycosis usually spreads through the respiratory tract, predominantly erodes the facial structures, causes discoloration or blackening over the nose, and blurred or double vision. In addition to these, the infected patient often exhibits chest pain, breathing difficulties, and hemoptysis (coughing up blood). Although not contagious, the outcome of the disease is often frightful as it causes gastrointestinal bleeding with severe respiratory distress. Moreover, if the infection disseminates systematically, the risk of affecting vital organs such as the spleen and heart is substantially high.

Considering the high population density and the high-speed dissemination rate of mucormycosis, we have tried to provide an epidemiological overview of black fungus infection in India in the first part of the review. In the second part, we have focused on drawing a comprehensive fact check of the current situation from the immunological perspective.[1]

fig:(1) Mucormycosis

➢ Common Symptoms of Mucormycosis

Until recently, the black fungus was a rare fungal ailment, with just a few cases documented around the world. Black fungus infection has such a high mortality rate that, it is critical to be aware of and warrants early diagnosis. One of the key issues associated with black fungus Infections is serious cosmetic problems as it affects different sections of the face. This is also known as “rhino-orbital-cerebral-mucormycosis” which is characterized by swelling and inflammation along the nasal line.

. In the following a brief overview of common signs is outlined:

A: -Formation of Black crust around the nose:

Swelling and black crust formation around the nasal tube are two of the most common symptoms of black fungus. If left untreated, the infection progresses to a more serious stage, resulting in nose mutilation and perhaps requiring surgery to repair the jawbone or other facial structures.

B: -Swelling and inflammation on cheeks and eyes:

Chronic swelling or inflammation around the eyes or cheeks could also be signs of black fungus. As a result of black fungus infection patients often exhibit numbness or inflammation on one side of the face with necrosis-like symptoms, which could also be the outcome of black fungus infection. [2]

C: - Partial or complete loss of vision:

If the black fungus targets the retinal nerves, it can cause partial or complete loss of vision. Any redness, irritation, or pain in one or both eyes are preliminary signs of such an outcome. [3]



Fig:(2) Symptoms of Mucormycosis

➢ Types of mucormycosis

1. **Rhinocerebral (sinus and brain) mucormycosis**
2. **Pulmonary (lung) mucormycosis**
3. **Cutaneous (skin) mucormycosis**
4. **Gastrointestinal mucormycosis**
5. **Disseminated mucormycosis.**

❖ Rhinocerebral (sinus and brain) mucormycosis

Rhinocerebral mucormycosis also known as zygomycosis, is an infection that affects the nose, and paranasal sinuses and can even spread to the brain (3). This type of mucormycosis is common in people with uncontrolled diabetes and in people who have undergone a kidney transplant. The infection starts in the nasal cavity at first and spreads towards the adjoined paranasal sinuses. Subsequently, implantation occurs in that area and grows at a faster rate in the sinuses and nasal cavity. The moist and humid environment inside the nasal cavity and paranasal sinuses is known to favor the growth and invasion of fungi. Angioinvasion is another way through which the infection can reach the brain. In this case, the progression is very rapid and has a unique model of pathogenesis. Rhino cerebral mucormycosis symptoms include black lesions on the upper inside of the buccal cavity with induction of mild to severe fever. More serious consequences in the form of brain infarction, hematoma, and orbital apex syndrome are not rare (4). Since vascular invasion is an important characteristic of this type of infection, the formation of intravascular thrombi often leads to infarction of the brain and ischemia (5). In some cases, if the aneurysmal blood vessels are ruptured, it may lead to hematoma along with intracerebral hemorrhages. Rhinocerebral mucormycosis also results in Meningitis which is a rare manifestation of this infection. The involvement of brain tissue leads to the formation of brain abscesses, especially in chronic cases (6). Brain abscess formation in such cases may be caused by some secondary bacterial infection (7). This infection may also affect the unilateral cranial nerves and cause hemiplegia (8). Mostly such outcome is mediated through the growth of mycelium along the invasion of leptomeningeal blood vessels (9). Diagnosis at an early stage, followed by proper treatment and surgical removal, if required, may help to save lives, and avoid permanent neurological complications.

❖ Pulmonary (lung) mucormycosis

Pulmonary mucormycosis mostly attacks the lungs of individuals affected with black fungus. This is the most common type of mucormycosis in people who have had a stem cell transplant or an organ transplant which also includes cancer patients (10). Pulmonary mucormycosis may develop due to inhalation of spores or lymphatic and hematogenous spread. The pathway of entry for Mucorales is primarily the respiratory tract where the fungi easily invade veins, arteries, and lymphatics resulting in infarction and thrombosis which can be fatal (12). Patients suffering from hematological malignancies, or diabetes mellitus, or who have received organ transplants and hematopoietic stem cell transplants are prone to invasive mucormycosis. The patients on corticosteroid-based therapy, chelation therapy, and neonatal prematurity can be other reasons for infection. In addition, in low-income countries like India, malnutrition is a major issue that can play a vital role in acquiring mucormycosis infection (13). Angioinvasion and sometimes direct tissue injury of the respiratory tract, are some of the consequences of this infection which may even extend from the lungs into the

great vessels (14). Clinical symptoms of the infection may include some nonspecific symptoms like fever, chest pain, and dyspnea (15). In a large experimental set-up, where 929 cases of zygomycosis were reviewed, the overall mortality rate was found to be 44% in the diabetic patients with zygomycosis as there was a 76% mortality rate in the case of pulmonary zygomycosis patients. The most common species responsible for zygomycosis is Rhizopus.

In a large experimental set-up, where 929 cases of zygomycosis were reviewed, the overall mortality rate was found to be 44% in the diabetic patients with zygomycosis as there was a 76% mortality rate in the case of pulmonary zygomycosis patients. The most common species responsible for zygomycosis is Rhizopus. [16]

Fig:(3) Pulmonary Mucormycosis

❖ Gastrointestinal mucormycosis:

Gastrointestinal mucormycosis mostly affects the stomach and intestine and is highly prevalent among newborns, especially premature infants who are less than 1 month of age (17). There was a prevalence of gastrointestinal mucormycosis in industrialized nations. However, during the last few years, the number of cases of gastric and gastrointestinal mucormycosis has increased around the globe (18). Other rare causes of gastrointestinal mucormycosis were seen in immunocompromised patients who were suffering from AIDS, systemic lupus erythematosus, and who had undergone organ transplantation (19). Some patients were seen to suffer from hepatic mucormycosis suggests an association with the ingestion of herbal medications (20). A study was conducted by Morton and colleagues, and they found a substantial increase in this infection in the 21st century (21). Recently, an outbreak of gastric mucormycosis occurred due to contamination of wooden applicators that had been used to mix drugs for patients with nasogastric feeding tubes (22). These patients suffered from massive gastric bleeds.

Fig:(4) Gastrointestinal Mucormycosis



❖ Cutaneous (skin) mucormycosis

This type of infection primarily affects the skin, especially in cases of skin trauma or surgery. This is one of the most common types of mucormycosis which occurs even in people with an immunocompromising history (23). Cutaneous mucormycosis is comparatively a new emerging fungal infection that is caused by fungi belonging to the phylum Glomeromycota. The clinical presentation is usually nonspecific, but a rapidly evolving necrosis indicates the presence of this infection. Given the occurrence of cutaneous mucormycosis, the strains that are most frequently isolated are Rhizopus oryzae, Apophysomyces elegans, and Lichtheimia corymbifera (24) Other isolates reported to be responsible are Saksenaea vasiformis, Mucor sp, Cunninghamella bertholletiae, Rhizopus microspores and Rhizomucor spp. (25). Reports are available to indicate that this type of fungus is associated with nitroglycerine patches and vascular devices (26). In a review that was done of 196 cases of healthcare-associated mucormycosis, it was found that 57% involved the skin. Among them, a predominant number of the population included surgical patients, premature infants, and immunocompromised hosts (27). Cutaneous mucormycosis is classified into two types- primary and secondary type infection. In the primary type of disease, the skin is often infected by direct inoculation and in the secondary form, the infection is caused by dissemination from other locations. According to the pattern of infection, it can be categorized as localized, deep, or disseminated. In a review that was conducted with 929 cases, 176 patients were found with skin involvement. The most affected areas of the skin due to this infection are the arms and legs (28). Other locations for spreading include the scalp, breast, neck, gluteal area, face, thorax, back, abdomen, and perineum (29).

fig:(5) Cutaneous Mucormycosis



❖ Disseminated mucormycosis.

It is a type of infection that spreads via the bloodstream to affect other parts of the body. The infection commonly affects the brain. It also can affect other organs such as the heart, skin, and spleen (30). Mucormycosis is a rapidly spreading

infection that is associatedwith extensive angioinvasion, thrombosis, tissue infarction, and necrosis (31). In worse cases, it leads to thehematogenous dissemination of the fungi (32). Dissemination may occur in up to 40% of patients who are suffering from hematological malignancies (33). In a review about children, it was found that dissemination increases the risk of death sevenfold (34). Patients with disseminated infection in the brain can even develop stress or coma in worse cases. (35).

❖ Symptomsof **Rhinocerebral (sinus and brain) mucormycosis** include:

- One-sided facial swelling
- Headache
- Nasal or sinus congestion
- Black lesions on the nasal bridge or upper inside of the mouth that quickly become more severe.
- Fever

❖ Symptoms of **Pulmonary (lung) mucormycosis** include:

- Fever
- Cough
- Chest pain
- Shortness of breath

❖ Symptoms of **Cutaneous (skin) mucormycosis** include:

- Blisters or ulcers
- Pain
- Excessive redness
- Swelling around the wound

❖ Symptoms of **gastrointestinal mucormycosis** include:

- Abdominal pain
- Nausea and vomiting
- Gastrointestinal bleeding

➢ Mechanism of Mucormycosis

Mucorales spores trigger an inflammatory response in healthy hosts. The most common underlying conditions for mucormycosis are associated with impaired or deficient phagocyte function. Infection is typically preceded by skin and soft tissue infection and illicit drug use. Several features of the fungus contribute to its aggressive growth in patients. These features include the innate thermotolerance of these fungi. The capabilities of these fungi for rapid growth and cell wall remodeling also help them to withstand hostile environments. The importance of iron acquisition in the pathogenesis of mucormycosis is supported by the unique susceptibility of iron-overloaded hosts to this invasive fungal pathogen. Given the importance of iron availability in the pathogenesis of mucormycosis, interventional strategies that could reduce free iron availability to Mucorales are therapeutically appealing. Administration of newer iron chelators without xenosiderophore properties has shown protective effects in animal models. However, lack of efficacy may be specific to neutropenic patients. (36,37,38,39,40)



Fig :(6) Mechanism of Mucormycosis

➢ Predisposing factors

Most (410/465, 88.2%) of the participants had underlying risk factors (Table 1). Uncontrolled diabetes mellitus was the most common risk factor for all forms of mucormycosis, except cutaneous and renal (Table 1). Interestingly, in 44 (12.9%) of the 342 individuals with diabetes, their diabetes was diagnosed during the evaluation of mucormycosis. The median (IQR) duration of diabetes was 48 (3–120) months, and 81.6% had uncontrolled disease (median (IQR) HbA1c, 10.2 (8–12)); 14.6% (50/342) presented with diabetic ketoacidosis. Fifty percent (7/14)

of the participants with isolated renal mucormycosis did not have an identifiable risk factor, whereas trauma (26/49, 53.1%) was the most common predisposing factor in cutaneous mucormycosis (Table 1).

➢ Table 1.

Risk factors, microbiology, diagnosis, and treatment characteristics of patients with mucormycosis according to the site of involvement. ROM, rhino-orbital mucormycosis; ROCM, rhino-orbital mucormycosis with cerebral extension

Empty Cell	Skin (*n* = 49)	ROM (*n* = 212)	Kidney (*n* = 14)	Gastrointestinal (*n* = 12)	Lung (*n* = 62)	ROCM (*n* = 103)	Disseminated (*n* = 13)	Total (*n* = 465)	p-value
Risk factors									
No risk factor	3 (6.1)	22 (10.4)	7 (50%)	3 (25)	5 (8.1)	11 (10.7)	4 (30.8)	55 (11.8)	0.0001
One risk factor	32 (65.3)	148 (69.8)	3 (21.4)	7 (58.3)	39 (62.9)	82 (79.6)	5 (39.5)	316 (68)	
Two risk factors	10 (20.4)	31 (14.6)	2 (14.3)	2 (16.7)	10 (16.1)	6 (5.8)	3 (23.1)	64 (13.8)	
Three or more risk factors	4 (8.2)	11 (5.1)	2 (14.3)	0	8 (12.9)	4 (3.9)	1 (7.7)	30 (6.4)	
Individual risk factors									
Diabetes mellitus	19 (38.8)	175 (82.5)	5 (35.7)	3 (25)	44 (71)	88 (85.4)	8 (61.5)	342 (73.5)	0.0001
Diabetes control									0.49
Uncontrolled	14	140	5	3	35	76	6	279	
Controlled	4	33	0	0	7	9	2	55	
Not known	1	2	0	0	2	3	0	8	
Diabetic ketoacidosis[a]	2 (10.5)	23 (13.1)	0	1 (33.3)	7 (15.9)	16 (18.2)	1 (12.5)	50 (14.6)	0.64
Transplant									
Solid organ	2 (4.1)	11 (5.2)	4 (28.6)	0	11 (17.7)	1 (1.0)	1 (7.7)	30 (6.5)	0.0001
Hematopoietic	1 (2)	4 (1.9)	0	0	1 (1.6)	0	0	6 (1.3)	0.84
Malignancy									
Hematological	2 (4.1)	18 (8.5)	1 (7.1)	1 (8.3)	9 (14.5)	3 (2.9)	1 (7.7)	35 (7.5)	0.20
Solid organ	1 (2)	2 (0.9)	0	1 (8.3)	1 (1.6)	1 (1.0)	1 (7.7)	7 (1.5)	0.23
Steroids	2 (4.1)	5 (2.4)	0	2 (16.7)	4 (6.5)	3 (2.9)	1 (7.7)	17 (3.7)	0.15
Immunosuppressants	3 (6.1)	12 (5.7)	4 (28.6)	0	11 (17.7)	3 (2.9)	1 (7.7)	34 (7.3)	0.0001
Trauma	26 (53.1)	2 (0.9)	0	1 (8.3)	0	3 (2.9)	0	32 (6.9)	0.0001
Burns	2 (4.1)	0	0	0	0	0	1 (7.7)	3 (0.6)	0.001
Presence of co-morbid illnesses	9 (18.4)	81 (38.2)	3 (21.4)	5 (41.7)	30 (48.4)	41 (39.8)	6 (46.2)	175 (37.6)	0.04
Aseptate hyphae on smear	39 (79.6)	198 (93.4)	5 (35.7)	3 (25)	54 (87.1)	97 (94.2)	10 (76.9)	406 (87.3)	0.0001

Empty Cell	Skin (*n* = 49)	ROM (*n* = 212)	Kidney (*n* = 14)	Gastrointestinal (*n* = 12)	Lung (*n* = 62)	ROCM (*n* = 103)	Disseminated (*n* = 13)	Total (*n* = 465)	p-value
Culture positivity	30 (61.2)	132 (62.3)	2 (14.3)	5 (41.7)	40 (64.5)	69 (67.0)	8 (61.5)	290 (62.4)	0.001
Histopathological diagnosis	33 (67.3)	165 (77.8)	13 (92.9)	9 (75.0)	34 (54.8)	73 (70.9)	13 (100)	340 (73.1)	0.001
Organism identified									0.16
Rhizopus[c]	11	114	0	2	32	65	7	231 (80.8)	0.28
Rhizopus arrhizus	8	88	0	2	20	54	4	176	
Rhizopus homothallicus	0	11	0	0	6	4	1	22	
Rhizopus microporus	3	15	0	0	6	6	2	32	
Rhizopus asexualis	0	0	0	0	0	1	0	1	
Rhizomucor spp.	1	2	0	0	1	0	0	4 (1.4)	
Apophysomyces variables	15	2	2	2	0	1	1	23 (7.9)	
Lichtheimiacorymbifera	1	4	0	0	4	1	0	10 (3.5)	
Saksenaeavasiformis	1	1	0	0	0	0	0	2 (0.7)	
Mucor spp.	1	9	0	1	3	2	0	16 (5.5)	
Cunninghamellaberthollетiae	1	1	0	0	1	0	0	3 (1.0)	
Syncephalastrumracemosum	0	1	0	0	0	0	0	1 (0.4)	
Treatment									
Surgery	39 (79.6)	152 (71.7)	9 (64.3)	8 (66.7)	13 (21.0)	60 (58.3)	8 (61.5)	289 (62.2)	0.0001
Any antifungal	38 (77.6)	183 (86.3)	12 (85.7)	9 (75.0)	54 (87.1)	87 (84.5)	11 (84.6)	394 (84.7)	0.74
Amphotericin B	35 (71.4)	177 (83.5)	12 (85.7)	8 (66.7)	51 (82.3)	87 (84.5)	11 (84.6)	381 (81.9)	0.37
Liposomal	15	114	10	4	32	55	8	238	0.04
Deoxycholate	20	63	2	4	19	32	3	143	0.30
Posaconazole	5 (10.2)	29 (13.7)	3 (21.4)	2 (16.7)	8 (12.9)	6 (5.8)	0	53 (11.4)	0.37
Voriconazole	2 (4.1)	9 (4.2)	0	0	6 (9.7)	0	0	17 (3.7)	0.06
Isavuconazole	0	0	0	0	0	0	1 (7.7)	1 (0.2)	0.0001
Itraconazole	0	6 (2.8)	0	0	0	2 (1.9)	0	8 (1.7)	0.65
Fluconazole	2 (4.1)	0	0	0	1 (1.6)	2 (1.9)	0	5 (1.1)	0.25
Caspofungin	0	2 (0.9)	0	0	1 (1.6)	0	0	3 (0.6)	0.88
Amphotericin and posaconazole combination	5 (10.2)	29 (13.7)	3 (21.4)	2 (16.7)	8 (12.9)	6 (5.8)	0	53 (11.4)	0.25
Duration of symptoms, days	14 (7–25)	12.5 (7–30)	15 (10–20)	14 (6.3–37.5)	15 (7–30)	10 (7–20)	15 (6.5–52.5)	12 (7–30)	0.74
Time to diagnosis, days	3 (1–6.5)	1 (1–3)	6.5 (2.8–16.5)	7 (3–13)	3 (1–9.3)	1 (1–1)	1 (1–1)	1 (1–1)	0.001
Duration of hospital stay, days	15 (6–23.5)	17 (5.3–31)	24 (7.5–46)	24 (9.8–33.5)	16 (8–35.5)	11 (3–30)	26 (11.5–51)	16 (6–32)	0.99
90-day mortality	28 (57.1)	82 (38.7)	7 (50)	8 (66.7)	38 (61.3)	71 (68.9)	8 (61.5)	242 (52)	0.98

❖ All values are represented as a number (%) or median (interquartile range) unless otherwise stated.

A: - Percentages are those among diabetic participants.

B: - Percentages are those among culture-positive cases. The remaining percentages are for the total number of participants having a particular site of involvement, mentioned in the first row of the table.

C: -Total species identified: 218; 13 species not identified for logistical reasons. (41,42)

➢ HOST-PATHOGEN INTERACTIONS

Mucormycosis infections are characterized by expansive angioinvasion that results in vessel thrombosis and posterior towel necrosis(43). Ischemic necrosis of infected apkins can help the delivery of leukocytes and antifungal agents to the foci of infection. This angioinvasion likely contributes to the capacity of the organism to hematogenous circulate to other target organs. Accordingly, damage of and penetration through endothelial cells or the extracellular matrix proteins lining blood vessels is likely to be a critical step in the pathogenetic strategy ofR. oryzae. thus, understanding the mechanisms by which these processes do may lead to new approaches to help and/ or treat mucormycosis. An earlier study showed thatR. oryzae can cleave to the extracellular matrix laminin and type IV collagen(44). We've set up thatR. oryzae strains cleave to mortal umbilical tone endothelial cells in vitro and foray these cells by convinced endocytosis(45). EndocytosedR. oryzae damages endothelial cells, and forestallment of endocytosis abrogates the capability of the organisms to beget endothelial cell damage(46). More lately, glucose- regulated protein(GRP78) was linked to act as a receptor that mediates penetration through and damage of endothelial cells by Mucorales (47). GRP78(also known as BiP/ HSPA5) was discovered as a cellular protein convinced by glucose starvation(48). It's a member of the HSP70 protein family that's substantially present in the endoplasmic reticulum. It functions as a major chaperone that's involved in numerous cellular processes, including protein folding and assembly, marking misfolded proteins for proteosome declination (49), regulating calcium homeostasis, and serving as a detector for endoplasmic reticulum stress(50). Despite its main function as a cellular chaperone protein, recent studies reported the translocation of a bit of GRP78 to the cell face in a variety of cells (51).

➢ Diagnosis

Beforehand opinion of mucormycosis is of utmost significance, since it may ameliorate outgrowth. Studies have shown that it increases survival (52), and it

may also reduce the need for or extent of surgical resection, defect, and suffering (53). Since the complaint is rare, a high indicator of dubitation is veritably important. opinion consists of recognition of threat factors, assessment of clinical instantiations, early use of imaging modalities, and prompt inauguration of individual styles grounded on histopathology, societies, and advanced molecular ways.

❖ Clinical Diagnosis

The clinical approach to opinion has low perceptivity and particularity. The hallmark of mucormycosis is towel necrosis performing from angioinvasion and thrombosis, the absence, still, of a necrotic eschar doesn't avert the opinion. Necrotic cutaneous lesions in immunocompromised cases may be due to mucormycosis, but the discriminational opinion includes other pathogens, similar as Aspergillus, Fusarium, Pseudallescheria, and Scedosporium species Pseudomonas aeruginosa causing ecthyma gangrenosum may also produce a analogous picture. Although the clinical signs and symptoms arenon-specific, some of them may have a potentially high prophetic value. In a susceptible host, a history of prophylaxis with voriconazole or the emergence of advance fungal infection while entering agents active against Aspergillus but not Mucorales, suggests the presence of mucormycosis(54,55,56,57,58).

❖ Background Treatment Strategies for Mucormycosis

The successful treatment of mucormycosis requires four steps:

1) early diagnosis.

2) reversal of underlying predisposing risk factors, if possible.

3) surgical debridement where applicable; and

4) prompt antifungal therapy [59].

❖ Early Diagnosis

A recent study from Chamilos etal.(60) quantified the benefit of early inauguration of polyene antifungal remedy. They reported that if treatment was initiated within 5 days of opinion of mucormycosis, survival was markedly bettered compared to inauguration of polyene remedy at ≥ 6 days after opinion(83 vs 49 survival). Hence, establishing an early opinion of mucormycosis is critical to enable early inauguration of active antifungal remedy.

❖ Reversal of Underlying Disease

It is critical to reverse/prevent underlying defects in host defense when treating patients with mucormycosis. Immunosuppressive medications, particularly corticosteroids, should be dose-reduced or stopped if possible. Aggressive management to rapidly restore euglycemia and normal acid-base status is critical in diabetic patients with ketoacidosis. Administration of iron should be avoided because it exacerbates the severity of infection in animal models of mucormycosis [61,62,63]. For the same reason, it may be advisable to minimize blood transfusions, if feasible.

❖ Surgical Management

Blood vessel thrombosis and performing towel necrosis during mucormycosis can affect in poor penetration of antifungal agents to the point of infection. thus, debridement of necrotic apkins may be critical for complete eradication of mucormycosis. In a recent study, surgery was set up to be an independent variable by logistic retrogression for favorable issues in cases with mucormycosis (64). likewise, in multiple case series, cases who didn't suffer surgical debridement of mucormycosis had a far advanced mortality rate than cases who passed surgery(65,66,67). Although there's implicit selection bias in these case series, as cases who didn't suffer surgery probably differed in complaint inflexibility or comorbidities from those who did, these data support the conception that surgical debridement is necessary to optimize cure rates.

❖ Antifungal Therapy

❖ First-Line Monotherapy Options

In general, primary antifungal remedy for mucormycosis should be grounded on a polyene, if possible. Although amphotericin B deoxycholate(AmB) was the foundation of mucormycosis remedy for decades, lipid phrasings of AmB are significantly lower nephrotoxic and can be safely administered at advanced boluses for a longer period than AmB(68). likewise, treatment of mucormycosis with liposomal amphotericin B(Angel) was associated with a 67 survival rate, compared to 39 survival when cases were treated with AmB($p = 0.02$). Multiple other, more recent case series also set up original remedy with Angel to be mainly more effective than other options(69,70). thus, utmost experts now prefer to use lipid polyenes rather than AmB for the treatment of mucormycosis. Available data indicate the advantages of Angel over amphotericin B lipid complex(ABLC) for the treatment of CNS mucormycosis. For illustration, Angel situations achieved in rabbit smarts were fivefold above ABLC situations (71) likewise, while also effective in neutropenic mice, Angel was markedly superior to ABLC in diabetic ketoacidosis(DKA) mice infected with Rhizopus oryzae, primarily because of superior concurrence of fungus from the brain(72). These

beast studies are rounded by a recent, fairly small retrospective case series, in which the issues of cases with rhino- orbital-cerebral mucormycosis were set up to be worse when ABLC was used as original remedy versus AmB or Angel(73). In discrepancy, a recent murine study set up that ABLC achieves superior lung situations than Angel, performing in superior concurrence of fungus from the lungs(74). When a advanced cure of Angel was used than ABLC, the efficacity was analogous. No clinical studies are available yet to validate these interesting murine data.

❖ Combination Antifungal Therapy for Mucormycosis

It's now known thatR. oryzae expresses the target enzyme for echinocandins(75). In DKA mice infected withR. oryzae, a combination of caspofungin plus ABLC remedy markedly bettered survival compared to either monotherapy or placebo(76). Combination remedy with Angel plus either micafungin or anidulafungin was also synergistic in either neutropenic or DKA mice with circulated mucormycosis(77). In a recent retrospective review from two institutions, combination polyene- caspofungin remedy was associated with significantly bettered issues in cases with rhino- orbital and rhino- orbital-cerebral mucormycosis compared to polyene monotherapy. utmost of the cases were diabetic, although some cases in the series had neutropenia or were solid organ transplant donors. In multivariate analysis, only combination remedy was significantly associated with superior issues(OR = 10.9 for successvs. monotherapy, p = 0.02).

❖ Treatment

Early Opinion, junking of prepping factors, timely antifungal remedy with surgical junking of all infected apkins, and spare curatives are four major factors in eradicating Mucormycosis.(78) Due to the vacuity of limited tools early discovery in 50 of cases is suspicious and is only diagnosed after postmortem examination. (79) Only in the case of rhino-cerebral and cutaneous infection it's possible to diagnose via imaging studies and nasal endoscopy.(80) Million etal. reported a polymerase chain response(PCR) system that detects morale DNA in blood samples three days before Mucormycosis opinion.(81) thus, if a COVID- 19 case with diabetes reports headache and visual abnormalities also the case must be estimated for Mucormycosis via imaging studies and nasal endoscopy. Beforehand discovery in similar cases may save lives because, in a after phase, the fungus may access the skull and may lead to death. Disposals or control of all prepping factors are also necessary for proper treatment of Mucormycosis infection. As diabetes with ketoacidosis is a major problem among Indian cases control over hyperglycemia with reversal of ketoacidosis may lead to reversal of mucorales to foray host apkins.(82) In this respect a study suggested that the use of Sodium bicarbonate with insulin may reverse diabetic ketoacidosis.(83) Limited or no use of Immunosuppressant medicines substantially steroids and

deferoxamine also explosively oppose the irruption of mucorales in the host apkins.(84) still, junking of infected apkins is the stylish possible treatment for mucormycosis, If possible. Still, this is easier in some cases similar as rhino-cerebral or cutaneous infection, but it's insolvable to operate in numerous cases similar as pulmonary complaint or if the contagion invades the psyches. (85) A study reported that early surgical excision of infected sinuses in rhino-cerebral mucormycosis prevents the infection from overrunning in eyes which results in advanced cure rates of 85. In a study, it was also reported that mortality was reduced to 14 from 70 if surgery was performed with antifungal agents.(86) In several studies, it was set up that the use of Amphotericin B is the favored antifungal medicine of choice for the treatment of mucormycosis infection. Liposomal amphotericin B with a low cure of 5 mg/ g/ day to a advanced cure of 10 mg/ kg/ day for cerebral infection cases is most favored because of low toxin and advanced CNS penetration.(87,88) still, the duration of treatment with Amphotericin B is still not duly reported and it was decided by the croaker grounded onthe underpinning condition of the case. Some reports proposed at least three weeks of treatment with Amphotericin B and if radiological and clinical enhancement was observed also farther treatment is conjoined with triazoles similar as posaconazole, isavuconazole, voriconazole,etc.(89) Studies revealed that posaconazole is the most prominent alternativeto Amphotericin B for the treatment of Mucormycosis infection(90) Clinical studies in beast models indicate that posaconazole is more effective than itraconazole and lower effective than amphotericinB. Intravenous or tablet lozenge form provides enhanced bioavailability to posaconazole medicine. 48 Significant in- vitro exertion against mucorales has been reported for Itraconazole, a broad- diapason triazole but in clinical trials, it fails to demotivate mucorales. Voriconazole failed to prove against Mucorales in an in- vitro model.(91) thus triazoles shouldn't be considered as a first- line agent against Mucormycosis. In an experimental murine model, Caspofungin alone showed minimum exertion against mucorales when tested in vitro. still, in combination with amphotericin B, it shows a synergistic effect. It has veritably little toxin. In an in- vitro exertion, a low cure of Caspofungin was set up effective by inhibiting(1 – 3)- β- D- glucan synthetase enzyme expressed by Rhizopus oryzae. Other spare curatives include iron chelator other than deferoxamine. Iron chelators didn't allow the fungus to take iron and not support its growth whereas deferoxamine promotes the growth ofmolds.Use of hyperbaric oxygen also suppresses the growth of Mucormycosis earth as advanced pressure of oxygen improves the capability of neutrophils to kill the molds.(92)

❖ Reference

1. Mondal A, Gireeshwar M, Govinderaj L. Black Fungus Mutilating COVID-19 Pandemic in India: Facts and Immunological Perspectives. Eur J Biol 2022; 81(1): 96-106. DOI: 10.26650/EurJBiol.2022.1083922

2. Guo H, Hu BJ, Yang XL, Zeng LP, Li B, Ouyang S, et al. Evolutionary Arms Race between Virus and Host Drives Genetic Diversity in Bat Severe Acute Respiratory Syndrome-Related Coronavirus Spike Genes. J Virol 2020; 94(20): e00902-20.

3. Cuervo NZ, Grandvaux N. Ace2: Evidence of role as an entry receptor for sars-cov-2 and implications in comorbidities. Elife 2020; 9: e61390.

4. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19(12): e405-e421.

5. Azhar EI, Hui DSC, Memish ZA, Drosten C, Zumla A. The Middle East Respiratory Syndrome (MERS). Infect Dis Clin North Am 2019;33(4):891-905.

6. Hui DSC, Zumla A. Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features. Infect Dis Clin North Am 2019; 33(4): 869-89.

7. Bennett M, Kaide CG, Matheson E, Bari V. Hyperbaric Oxygen Therapy and Utilization in Infectious Disease. Curr Emerg Hosp Med Rep 2018; 6(3).

8. Warnatsch A, Tsourouktsoglou TD, Branzk N, Wang Q, Reincke S, Herbst S, et al. Reactive Oxygen Species Localization Programs Inflammation to Clear Microbes of Different Size. Immunity 2017; 46(3): 421-32.

9. Castrejón-Pérez AD, Miranda I, Welsh O, Welsh EC, Ocampo-Candiani J. Cutaneous mucormycosis. A Bras Dermatol 2017; 92(3): 304-11.

10. Lionakis MS, Iliev ID, Hohl TM. Immunity against fungi. JCI Insight 2017; 2(11): e93156.

11. Yamin HS, Alastal AY, Bakri I. Pulmonary mucormycosis over 130 years: A case report and literature review. Turk Thorac J 2017; 18(1): 1-5.

12. Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol 2016; 6: 98.

13. Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest 2016; 126(6): 2280-94.

14. Roth S, Bergmann H, Jaeger M, Yeroslaviz A, Neumann K, Koenig PA, et al. Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. Cell Rep 2016; 17(10): 2572-83.

15. Erwig LP, Gow NAR. Interactions of fungal pathogens with phagocytes. Nat Rev Microbiol 2016; 14(3): 163-76.

16. Wang XM, Guo LC, Xue SL, Chen Y bin. Pulmonary mucormycosis: A case report and review of the literature. Oncol Lett 2016; 11(5): 3049-53.

17. Yang HN, Wang CL. Looks like tuberculous meningitis, but not: A case of rhinocerebral mucormycosis with garcin syndrome. Front Neurol 2016; 7: 181.

18. Mattingly JK, Ramakrishnan VR. Rhinocerebral Mucormycosis of the Optic Nerve. Otolaryngol Head Neck Surg 2016;155(5):888-9

19. Paczosa MK, Mecsas J. Klebsiella pneumoniae: Going on the Offense with a Strong Defense. Microbiol Mol Biol Rev 2016; 80(3): 629-61.

20. Alaa Abdul-Hussein Al-Daamy, Haider Abd-Al Ameer, Hasan Zuher, Hussein Monather, Bashaer Ahmmed, Niesreen Kadhim. Antifungal activity of propolis against Dermatophytes and Candida albicans isolated from human mouth. J contemp med sci 2015; 1(3).

21. Deng Z, Ma S, Zhou H, Zang A, Fang Y, Li T, et al. Tyrosine phosphatase SHP-2 mediates C-type lectin receptor-induced activation of the kinase Syk and anti-fungal T H 17 responses. Nat Immunol 2015; 16(6): 642-52.

22. Underhill DM, Pearlman E. Immune Interactions with Pathogenic and Commensal Fungi: A Two-Way Street. Immunity 2015;43(5):845-58.

23. Shin S, Jung S, Menzel F, Heller K, Lee H, Lee S. Molecular phylogeny of black fungus gnats (Diptera: Sciaroidea: Sciaridae) and the evolution of larval habitats. Mol Phylogenet Evol 2013; 66(3): 833 - 46.

24. Guymer C, Khurana S, Suppiah R, Hennessey I, Cooper C. Successful treatment of disseminated mucormycosis in a neutropenic patient with T-cell acute lymphoblastic leukemia. BMJ Case Rep 2013; 2013: bcr2013009577.

25. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol 2013; 8(9): 1163-75.

26. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S16-22.

27. Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing Cutaneous Mucormycosis after a Tornado in Joplin, Missouri, in 2011. N Engl J Med 2012; 367(23): 2214-25.

28. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S23-34.

29. Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, et al. Healthcare-associated mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S44-54.

30. Hibbett DS, Binder M, Bischoff JF. A higher-level phylogenetic classification of the fungi. Mycol Res 2007; 111:509–47.

31. Song Y, Qiao J, Giovanni G, Liu G, Yang H, Wu J, et al. Mucormycosis in renal transplant recipients: a review of 174 reported cases external icon. BMC Infect Dis 2017; 17:283.

32. Abdalla A, Adelmann D, Fahal A, Verbrugh H, Van Belkum A, De Hoog S. Environmental occurrence of Madurella mycetomatis, the major agent of human eumycetoma in Sudan external icon. J Clin Microbiol 2002; 40:1031–6.

33. Abramowitz I. Fatal perforations of the stomach due to mucormycosis of the gastrointestinal tract. S Afr Med J 1964; 38:93–4.

34. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and external management icon. Clin Microbiol Rev 2005; 18:556-69.

35. Dora E Corzo-León, Luis D Chora-Hernández, Ana P Rodríguez-Zulueta, Thomas J Walsh

36. *Medical Mycology*, Volume 56, Issue 1, January 2018, Pages 29–43, https://doi.org/10.1093/mmy/myx017

37. *Medical Mycology*, Volume 44, Issue 4, June 2006, Pages 335–342, https://doi.org/10.1080/13693780500464930

38. Ben-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect. 2009; 59:134–8.

39. Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol. 1996; 70:76–83.

40. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE., Jr Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun. 2005; 73:778–83.

41. Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010; 120:1914–24.

42. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res. 2007; 67:3496–9.

43. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007; 581:3641–51.

44. Li J, Lee AS. Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med. 2006; 6:45–54.

45. Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal. 2009; 11:2307–16.

46. Marty, F.M.; Cosimi, L.A.; Baden, L.R. Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants. *N. Engl. J. Med.* **2004**, *350*, 950–952.

47. Imhof, A.; Balajee, S.A.; Fredricks, D.N.; Englund, J.A.; Marr, K.A. Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole. *Clin. Infect. Dis.* **2004**, *39*, 743–746.

48. Siwek, G.T.; Dodgson, K.J.; De Margarida, M.-S.; Bartelt, L.A.; Kilborn, S.B.; Hoth, P.; Diekema, D.J.; Pfaller, M.A. Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis. *Clin. Infect. Dis.* **2004**, *39*, 584–587.

49. Chamilos, G.; Lewis, R.E.; Kontoyiannis, D.P. Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. *Clin. Infect. Dis.* **2008**, *47*, 503–509.

50. Walsh, T.J.; Gamaletsou, M.N.; McGinnis, M.R.; Hayden, R.T.; Kontoyiannis, D.P. Early Clinical and Laboratory Diagnosis of Invasive Pulmonary, Extrapulmonary, and Disseminated Mucormycosis (Zygomycosis). *Clin. Infect. Dis.* **2012**, *54*, S55–S60.

51. Spellberg B, Edwards J Jr., Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005, 18:556–569.

52. Article CAS PubMed Google Scholar

53. Chamilos G, Lewis RE, Kontoyiannis DP: Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503–509. This article describes a very compelling study precisely defining the necessary timing of initiation of therapy for mucormycosis to maximize outcomes in the cancer setting.

54. Boelaert JR, de Locht M, Van Cutsem J, et al.: Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993, 91:1979–1986.

55. Article CAS PubMed Google Scholar

56. Van Cutsem J, Boelaert JR: Effects of deferoxamine, feroxamine, and iron on experimental mucormycosis (zygomycosis). Kidney Int 1989, 36:1061–1068.

57. Article PubMed Google Scholar

58. Ibrahim AS, Gebermariam T, Fu Y, et al.: The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007, 117:2649–2657. This seminal study defines the potential for iron chelation to serve as synergistic, adjunctive therapy for mucormycosis.

59. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41:634–653. Doi: 10.1086/432579.

60. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000; 30:851–856. Doi: 10.1086/313803.

61. Nithyanandam S, Jacob MS, Battu RR, et al. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003; 51:231–236.

62. Asai K, Suzuki K, Takahashi T, et al. Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. Jpn J Thorac Cardiovasc Surg. 2003; 51:163–166. Doi: 10.1007/s11748-003-0055-y.

63. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998; 26:1383–1396. Doi: 10.1086/516353.

64. Pagano L, Valentini CG, Posteraro B, et al. Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) J Chemother. 2009; 21:322–329.

65. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients: a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009; 200:1002–1011. Doi: 10.1086/605445.

66. Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000; 182:274–282. Doi: 10.1086/315643.

67. Ibrahim AS, Gebremariam T, Husseiny MI, et al. Comparison of lipid amphotericin B preparations in treating murine zygomycosis. Antimicrob Agents Chemother. 2008; 52:1573–1576. Doi: 10.1128/AAC.01488-07.

68. Reed C, Bryant R, Ibrahim AS, et al.: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008, 47:364–371. This retrospective study describes superior outcomes in patients with mucormycosis treated with combination polyene-echinocandin therapy.

69. Lewis RE, Liao G, Hou J, et al. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother. 2007; 51:1253–1258. Doi: 10.1128/AAC.01449-06.

70. Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1, 3-beta-D-glucan synthase, lowers burden in the brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005; 49:721–727. Doi: 10.1128/AAC.49.2.721-727.2005.

71. Spellberg B, Fu Y, Edwards JE., Jr Ibrahim AS: Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidosis mice. Antimicrob Agents Chemother. 2005; 49:830–832. Doi: 10.1128/AAC.49.2.830-832.2005.

72. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008; 52:1556–1558. Doi: 10.1128/AAC.01458-07.

73. Nithyanandam S., Jacob M.S., Battu R.R., Thomas R.K., Correa M.A., D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003; 51:231–236.

74. Mori T., Egashira M., Kawamata N., et al. Zygomycosis: two case reports and review of reported cases in the literature in Japan. Nihon Ishinkin Gakkai Zasshi. 2003; 44:163–179. doi: 10.3314/jjmm.44.163.

75. Khor B.S., Lee M.H., Leu H.S., Liu J.W. rhinocerebral mucormycosis in Taiwan. J Microbiol Immunol Infect. 2003; 36:266–269.

76. Millon L., LaRosa F., Lepiller Q., et al. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients. Clin. Infect. Dis. 2013;56: e95–e101. doi: 10.1093/cid/cit094.

77. Spellberg B., Edwards J., Jr., Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556–569. Doi: 10.1128/CMR.18.3.556-569.2005.

78. Gebremariam T., Lin L., Liu M., et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. J Clin Invest. 2016; 126:2280–2294. doi: 10.1172/JCI82744.

79. Ribes J.A., Vanover-Sams C.L., Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13:236–301. Doi: 10.1128/CMR.13.2.236.

80. Millon L., Herbrecht R., Grenouillet F., et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF) Clin Microbiol Infect. 2016;22(9): 810.E1–810.E8.

81. Nithyanandam S., Jacob M.S., Battu R.R., Thomas R.K., Correa M.A., D'Souza O. Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol. 2003; 51:231–236.

82. Bouza E., Munoz P., Guinea J. Mucormycosis: an emerging disease? Clin Microbiol Infect. 2006;12(suppl 7):7–23. doi: 10.1111/j.1469-0691.2006.01604. x.

83. Barron M.A., Lay M., Madinger N.E. Surgery and treatment with high-dose liposomal amphotericin B for eradication of craniofacial zygomycosis in a patient with Hodgkin's disease who had undergone allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2005; 43:2012–2014. doi: 10.1128/JCM.43.4.2012-2014.2005.

84. Cagatay A.A., Oncu S.S., Calangu S.S., Yildirmak T.T., Ozsut H.H., Eraksoy H.H. rhinocerebral mucormycosis treated with 32-gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis. 2001; 1:22. doi: 10.1186/1471-2334-1-22.

85. Kontoyiannis D.P., Lewis R.E. How I treat mucormycosis. Blood. 2011;118(5):1216–1224. doi: 10.1182/blood-2011-03-316430.

86. Cornely O.A., Alastruey I.A., Arenz D., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019;19: e405–e421.

87. Dannaoui E., Meis J.F., Loebenberg D., Verweij P.E. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother. 2003; 47:3647–3650. doi: 10.1128/AAC.47.11.3647-3650.2003.

88. Pfaller M.A., Messer S.A., Hollis R.J., Jones R.N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2002; 46:1032–1037. doi: 10.1128/AAC.46.4.1032-1037.2002. 2000.

89. Spellberg B., Fu Y., Edwards J.E., Jr., Ibrahim A.S. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidosis mice. Antimicrob Agents Chemother. 2005; 49:830–832. doi: 10.1128/AAC.49.2.830-832.2005.

90. Ibrahim A.S., Bowman J.C., Avanessian V., et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers the burden in the brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother. 2005; 49:721–727. doi: 10.1128/AAC.49.2.721-727.2005.

91. Boelaert J.R., Cutsem J.V., Locht D.M., Schneider Y.J., Crichton R.R. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int. 1994; 45:667–671. doi: 10.1038/ki.1994.89.

92. Ferguson B.J., Mitchell T.G., Moon R., Camporesi E.M., Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis. 1988 May-Jun;10(3):551–559. doi: 10.1093/clinids/10.3.551. DOI: 10.1093/clinids/10.3.551.